- Supported exchanges /
- F /
- 6OP.F
OSE IMMUNOTHERAPE.EO -20 (6OP F) stock market data APIs
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
OSE IMMUNOTHERAPE.EO -20 Financial Data Overview
| 9.88 | |
| 9.88 | |
| - | |
| 9.88 | |
| 9.88 | |
| 3.145-10.46 | |
| 223 M | |
| 5.8497 | |
| 21 802 K | |
| 83 442 K | |
| 0.904 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
OSE IMMUNOTHERAPE.EO -20 Fundamental Data is available in our Financial Data APIs
- Net Revenue 83 442 K
- EBITDA 52 956 K
- Earnings Per Share 1.73
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get OSE IMMUNOTHERAPE.EO -20 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get OSE IMMUNOTHERAPE.EO -20 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
